885039-03-2

Basic information

• Product Name: 4-chloro-2-(4-chloro-2,5-difluorophenyl)-6,7-dihydrothieno[3,2-d]pyrimidine
• Synonyms: 4-chloro-2-(4-chloro-2,5-difluorophenyl)-6,7-dihydrothieno[3,2-d]pyrimidine
• CAS NO: 885039-03-2
• Molecular Weight: 319.162
• Mol File: 885039-03-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-chloro-2-(4-chloro-2,5-difluorophenyl)-6,7-dihydrothieno[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-2-(4-chloro-2,5-difluorophenyl)-6,7-dihydrothieno[3,2-d]pyrimidine(885039-03-2)
• EPA Substance Registry System: 4-chloro-2-(4-chloro-2,5-difluorophenyl)-6,7-dihydrothieno[3,2-d]pyrimidine(885039-03-2)

Safety Data

• Hazardous Substances Data: 885039-03-2(Hazardous Substances Data)

Upstream product

• 885038-84-6 2-(4-chloro-2,5-difluorophenyl)-6,7-dihydrothieno[3,2-d]pyrimidin-4(3H)-one 
• 2689-69-2 methyl tetrahydrothiophen-3-one-2-carboxylate 
• 764648-44-4 4-chloro-2,5-difluorobenzamidine 

Downstream Products

• 1411734-18-3 2-(4-chloro-2,5-difluorophenyl)-4-(morpholin-4-yl)-6,7-dihydrothieno[3,2-d]pyrimidine hydrochloride 

Relevant articles and documents

Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists

A series of fused-pyrimidine derivatives have been discovered as potent and orally active GPR119 agonists. A combination of the fused-pyrimidine structure and 4-chloro-2,5-difluorophenyl group provided the 5,7-dihydrothieno[3,4-d] pyrimidine 6,6-dioxide derivative 14a as a highly potent GPR119 agonist. Further optimization of the amino group at the 4-position in the pyrimidine ring led to the identification of 2-{1-[2-(4-chloro-2,5-difluorophenyl)-6,6-dioxido-5,7- dihydrothieno[3,4-d]pyrimidin-4-yl]piperidin-4-yl}acetamide (16b) as an advanced analog. Compound 16b was found to have extremely potent agonistic activity and improved glucose tolerance at 0.1 mg/kg po in mice. We consider compound 16b and its analogs to have clear utility in exploring the practicality of GPR119 agonists as potential therapeutic agents for the treatment of type 2 diabetes mellitus.